Agile Therapeutics
AGRX
AGRX was delisted on the 25th of March, 2024.
38 hedge funds and large institutions have $8.81M invested in Agile Therapeutics in 2018 Q2 according to their latest regulatory filings, with 6 funds opening new positions, 9 increasing their positions, 9 reducing their positions, and 14 closing their positions.
0% more repeat investments, than reductions
Existing positions increased: 9 | Existing positions reduced: 9
17% less funds holding
Funds holding: 46 → 38 (-8)
50% less funds holding in top 10
Funds holding in top 10: 4 → 2 (-2)
57% less first-time investments, than exits
New positions opened: 6 | Existing positions closed: 14
86% less capital invested
Capital invested by funds: $63.4M → $8.81M (-$54.6M)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Renaissance Technologies
New York
|
+$600K |
| 2 |
Deutsche Bank
Frankfurt Am Main Ge,
Germany
|
+$189K |
| 3 |
Acadian Asset Management
Boston,
Massachusetts
|
+$133K |
| 4 |
Vanguard Group
Malvern,
Pennsylvania
|
+$87.7K |
| 5 |
WS
Wedbush Securities
Los Angeles,
California
|
+$87.7K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Franklin Resources
San Mateo,
California
|
-$4.81M |
| 2 |
CC
Caxton Corporation
Princeton,
New Jersey
|
-$4.66M |
| 3 |
AC
Aisling Capital
New York
|
-$3.35M |
| 4 |
JGC
J. Goldman & Co
New York
|
-$993K |
| 5 |
Alyeska Investment Group
Chicago,
Illinois
|
-$666K |
AGRX Hedge Fund Activity: Q2 2018 in Review
38 of the 4,385 institutional investors tracked by Wall St. Rank reported a position in Agile Therapeutics (AGRX) for Q2 2018, worth a combined $8.81M — down 86% from $63.4M a quarter earlier.
Sellers outnumbered buyers: 14 funds closed out of AGRX and 6 opened new positions — a net loss of 8 holders — while 9 trimmed existing stakes and 9 added.
The largest buyer was Renaissance Technologies, adding an estimated $600K. The largest seller was Franklin Resources, cutting an estimated $4.81M.
- 38 institutional investors held Agile Therapeutics (AGRX) as of Q2 2018, down from 46 in Q1 2018.
- Funds reported $8.81M of Agile Therapeutics stock for Q2 2018, down 86% quarter-over-quarter.
- 6 funds opened new Agile Therapeutics positions in Q2 2018 and 14 closed out, a net change of -8 holders.
- The largest Agile Therapeutics buyer in Q2 2018 was Renaissance Technologies, an estimated $600K added.
- The largest Agile Therapeutics seller in Q2 2018 was Franklin Resources, an estimated $4.81M sold.
Based on aggregated 13F filings for Q2 2018.